Genovis AB (publ.) Future Growth

Future criteria checks 2/6

Genovis AB (publ.) is forecast to grow earnings and revenue by 13.6% and 19.6% per annum respectively. EPS is expected to grow by 19.9% per annum. Return on equity is forecast to be 18% in 3 years.

Key information

13.6%

Earnings growth rate

19.9%

EPS growth rate

Life Sciences earnings growth	46.6%
Revenue growth rate	19.6%
Future return on equity	18.0%
Analyst coverage	Low
Last updated	17 May 2024

Recent future growth updates

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Recent updates

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

May 09

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Aug 09

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Mar 27

How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?

Dec 30

Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?

Nov 23

Earnings and Revenue Growth Forecasts

OM:GENO - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	221	44	40	54	3
12/31/2025	189	49	44	57	3
12/31/2024	154	41	31	57	3
3/31/2024	128	31	27	39	N/A
12/31/2023	159	62	55	68	N/A
9/30/2023	158	54	40	53	N/A
6/30/2023	151	57	40	49	N/A
3/31/2023	142	42	42	47	N/A
12/31/2022	104	11	-5	-1	N/A
9/30/2022	119	41	40	43	N/A
6/30/2022	112	36	40	43	N/A
3/31/2022	111	36	37	41	N/A
12/31/2021	94	25	41	46	N/A
9/30/2021	71	11	3	6	N/A
6/30/2021	69	12	1	7	N/A
3/31/2021	65	9	-12	9	N/A
12/31/2020	61	6	-17	4	N/A
9/30/2020	54	-3	-16	7	N/A
6/30/2020	64	3	-11	9	N/A
3/31/2020	60	6	4	9	N/A
12/31/2019	61	10	8	13	N/A
9/30/2019	58	12	7	10	N/A
6/30/2019	43	5	0	4	N/A
3/31/2019	40	1	2	3	N/A
12/31/2018	35	-2	-3	-1	N/A
9/30/2018	31	-4	-4	-2	N/A
6/30/2018	27	-6	-6	-5	N/A
3/31/2018	24	-7	-10	-9	N/A
12/31/2017	23	-8	N/A	-8	N/A
9/30/2017	21	-9	N/A	-9	N/A
6/30/2017	21	-9	N/A	-11	N/A
3/31/2017	20	-14	N/A	-15	N/A
12/31/2016	19	-15	N/A	-16	N/A
9/30/2016	17	-16	N/A	-18	N/A
6/30/2016	16	-21	N/A	-18	N/A
3/31/2016	14	-18	N/A	-14	N/A
12/31/2015	14	-20	N/A	-16	N/A
9/30/2015	13	-25	N/A	-18	N/A
6/30/2015	11	-24	N/A	-20	N/A
3/31/2015	10	-23	N/A	-21	N/A
12/31/2014	10	-22	N/A	-22	N/A
9/30/2014	8	-20	N/A	-18	N/A
6/30/2014	10	-17	N/A	-17	N/A
3/31/2014	11	-16	N/A	-14	N/A
12/31/2013	10	-16	N/A	-12	N/A
9/30/2013	10	-19	N/A	-15	N/A
6/30/2013	9	-19	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GENO's forecast earnings growth (13.6% per year) is above the savings rate (1%).

Earnings vs Market: GENO's earnings (13.6% per year) are forecast to grow slower than the Swedish market (14.3% per year).

High Growth Earnings: GENO's earnings are forecast to grow, but not significantly.

Revenue vs Market: GENO's revenue (19.6% per year) is forecast to grow faster than the Swedish market (2.1% per year).

High Growth Revenue: GENO's revenue (19.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GENO's Return on Equity is forecast to be low in 3 years time (18%).

Genovis AB (publ.) Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 11%

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 16% to kr61.50

Price target decreased by 7.5% to kr68.00

Consensus revenue estimates fall by 35%

Price target decreased by 8.5% to kr73.50

Recent updates

Consensus revenue estimates fall by 11%

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 16% to kr61.50

Group Chief Financial Officer recently bought kr130k worth of stock

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Price target decreased by 7.5% to kr68.00

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 35%

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Price target decreased by 8.5% to kr73.50

Consensus revenue estimates fall by 13%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Consensus EPS estimates increase by 22%

Director recently sold kr27m worth of stock

New major risk - Earnings quality

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Consensus EPS estimates increase by 21%

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought kr308k worth of stock

Independent Chairman of the Board recently bought kr308k worth of stock

Vice President of Sales & Marketing recently bought kr89k worth of stock

President & CEO recently bought kr118k worth of stock

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 8.6% to kr76.00

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Price target decreased to kr60.00

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Consensus forecasts updated

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Price target decreased to kr80.00

Genovis AB (Publ.) Announces Board Changes

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

Consensus forecasts updated

Group Chief Financial Officer recently bought kr96k worth of stock

First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021)

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought kr52k worth of stock

Insider recently bought kr52k worth of stock

General Counsel recently bought kr320k worth of stock

Consensus revenue estimates fall by 20%

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind